Apexigen adds to Chinese antibody alliances with Duyiwei deal
This article was originally published in Scrip
In a deal indicative of Chinese firms' growing interest in novel biologics, the privately held US antibody venture Apexigen has licensed a product with potential in oncology to Gansu Duyiwei Biological Pharmaceutical for development and commercialisation in China.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.